Novartis Lower Despite FDA Approval For Treatment Of Leukemia

Novartis AG (ADR) NVS shares are trading lower by 80 cents at $82.82 in Wednesday's session.

Despite FDA approval for CAR T-Cell therapy to treat certain children and young adults with B-cell acute Lymphoblastic Leukemia, the stock is in the red.

After a lower open, Novartis could revisit Tuesday's close ($83.62) as $83.00 stands at the high for the session as of 12:15 p.m. EST. On the downside, it has found intraday support just under its August 18 low ($82.65) as $82.61 stands as the low for the session.

If the decline continues, there may be additional support at its July 13 low of $82.29.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!